Subcutaneous injection bypasses the gastrointestinal tract entirely
The answer is largely financial
No claims are made regarding therapeutic, diagnostic, or clinical applications
Sikiric P, Seiwerth S, Grabarevic Z, Petek M, Rucman R, Turkovic B, et al
However, its low toxicity , strong safety profile in animal studies, and lack of severe side effects have made it one of the most accessible peptides for first-time users interested in soft tissue recovery
This change means compounding pharmacies will face stricter guidelines, potentially limiting patient access to these therapies unless they are prescribed under specific, FDA-approved conditions or clinical trials